Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease

Michelle Meyer; Eric Huang; Olga Yuzhakov; Palaniappan Ramanathan; Giuseppe Ciaramella; Alexander Bukreyev

doi:10.1093/infdis/jix592

Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease

Michelle Meyer, Eric Huang, Olga Yuzhakov, Palaniappan Ramanathan, Giuseppe Ciaramella, Alexander Bukreyev

Pathology

Research output: Contribution to journal › Article › peer-review

137 Scopus citations

Abstract

Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of Guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.

Original language	English (US)
Pages (from-to)	451-455
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	217
Issue number	3
DOIs	https://doi.org/10.1093/infdis/jix592
State	Published - Jan 17 2018

Keywords

Ebola virus
RNA
antibody response
immunization
vaccine

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/infdis/jix592

Cite this

@article{5625d1f083cd4a03bee7fb52139a9c85,

title = "Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease",

abstract = "Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of Guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.",

keywords = "Ebola virus, RNA, antibody response, immunization, vaccine",

author = "Michelle Meyer and Eric Huang and Olga Yuzhakov and Palaniappan Ramanathan and Giuseppe Ciaramella and Alexander Bukreyev",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2018",

month = jan,

day = "17",

doi = "10.1093/infdis/jix592",

language = "English (US)",

volume = "217",

pages = "451--455",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease

AU - Meyer, Michelle

AU - Huang, Eric

AU - Yuzhakov, Olga

AU - Ramanathan, Palaniappan

AU - Ciaramella, Giuseppe

AU - Bukreyev, Alexander

PY - 2018/1/17

Y1 - 2018/1/17

N2 - Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of Guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.

AB - Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of Guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.

KW - Ebola virus

KW - RNA

KW - antibody response

KW - immunization

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85041227397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041227397&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix592

DO - 10.1093/infdis/jix592

M3 - Article

C2 - 29281112

AN - SCOPUS:85041227397

SN - 0022-1899

VL - 217

SP - 451

EP - 455

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 3

ER -

Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this